



Sustained Control of Pyruvate Carboxylase by the Essential Second Messenger Cyclic di-AMP in *Bacillus subtilis*

Larissa Krüger,^a Christina Herzberg,^a Dennis Wicke,^a Patricia Scholz,^b Kerstin Schmitt,^c Asan Turdiev,^d Vincent T. Lee,^d Till Ischebeck,^b Jörg Stülke^a

^aDepartment of General Microbiology, Institute for Microbiology & Genetics, GZMB, Georg-August-University Göttingen, Göttingen, Germany

^bDepartment of Plant Biochemistry, GZMB, Georg-August-University Göttingen, Göttingen, Germany

^cDepartment of Molecular Microbiology and Genetics, Service Unit LCMS Protein Analytics, Institute for Microbiology & Genetics, GZMB, Georg-August-University Göttingen, Göttingen, Germany

^dDepartment of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland, USA

ABSTRACT In *Bacillus subtilis* and other Gram-positive bacteria, cyclic di-AMP is an essential second messenger that signals potassium availability by binding to a variety of proteins. In some bacteria, *c*-di-AMP also binds to the pyruvate carboxylase to inhibit its activity. We have discovered that in *B. subtilis* the *c*-di-AMP target protein DarB, rather than *c*-di-AMP itself, specifically binds to pyruvate carboxylase both *in vivo* and *in vitro*. This interaction stimulates the activity of the enzyme, as demonstrated by *in vitro* enzyme assays and *in vivo* metabolite determinations. Both the interaction and the activation of enzyme activity require apo-DarB and are inhibited by *c*-di-AMP. Under conditions of potassium starvation and corresponding low *c*-di-AMP levels, the demand for citric acid cycle intermediates is increased. Apo-DarB helps to replenish the cycle by activating both pyruvate carboxylase gene expression and enzymatic activity via triggering the stringent response as a result of its interaction with the (p)ppGpp synthetase Rel and by direct interaction with the enzyme, respectively.

IMPORTANCE If bacteria experience a starvation for potassium, by far the most abundant metal ion in every living cell, they have to activate high-affinity potassium transporters, switch off growth activities such as translation and transcription of many genes or replication, and redirect the metabolism in a way that the most essential functions of potassium can be taken over by metabolites. Importantly, potassium starvation triggers a need for glutamate-derived amino acids. In many bacteria, the responses to changing potassium availability are orchestrated by a nucleotide second messenger, cyclic di-AMP. *c*-di-AMP binds to factors involved directly in potassium homeostasis and to dedicated signal transduction proteins. Here, we demonstrate that in the Gram-positive model organism *Bacillus subtilis*, the *c*-di-AMP receptor protein DarB can bind to and, thus, activate pyruvate carboxylase, the enzyme responsible for replenishing the citric acid cycle. This interaction takes place under conditions of potassium starvation if DarB is present in the apo form and the cells are in need of glutamate. Thus, DarB links potassium availability to the control of central metabolism.

KEYWORDS *Bacillus subtilis*, cyclic di-AMP, TCA cycle, protein-protein interaction, pyruvate carboxylase, *c*-di-AMP, second messenger

In most organisms, the tricarboxylic acid (TCA) cycle is the central hub in metabolism. The cycle provides the cells with reducing power for respiration and to fuel anabolic reactions, and it generates precursors for important anabolic reactions, such as 2-oxoglutarate and oxaloacetate, for the biosynthesis of glutamate and aspartate and the derived amino acids, respectively. Accordingly, at least a partial TCA cycle is present in most organisms, with the notable

Invited Editor Joshua J. Woodward, University of Washington

Editor Carmen Buchrieser, Institut Pasteur

Copyright © 2022 Krüger et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Jörg Stülke, jstuelk@gwdg.de.

The authors declare no conflict of interest.

Received 2 December 2021

Accepted 12 January 2022

Published 8 February 2022

exception of genome-reduced symbionts or pathogens that depend completely on their partner or host to acquire all metabolites.

The use of intermediates of the TCA cycles for anabolic purposes makes it essential to replenish the cycle to compensate for the loss of carbon backbones. The most important branch point of the cycle is 2-oxoglutarate, which can be either oxidized to succinyl-CoA within the TCA cycle or reduced to form glutamate, by far the most abundant metabolite in any living cell (1, 2). In particular, very high glutamate concentrations are required under conditions of osmotic stress when glutamate serves as the precursor for the production of molar levels of the osmoprotective amino acid proline (3). Moreover, the cells experience a high demand of glutamate under conditions of potassium limitation. Under this condition, positively charged amino acids derived from glutamate replace potassium to buffer the negative charge of the DNA (4). Accordingly, the cells are in high demand to replenish the carbon backbones for the TCA cycle under these conditions.

The Gram-positive model bacterium *Bacillus subtilis* has a complete TCA cycle. The TCA cycle in this bacterium is controlled at the levels of transcription and RNA degradation and by protein-protein interactions (5–9). The anaplerotic production of oxaloacetate from pyruvate to replenish the cycle is catalyzed by pyruvate carboxylase (PC), encoded by the *pycA* gene. Expression of the *pycA* gene is under positive stringent control, i.e., expression is increased under conditions of amino acid or potassium starvation as a result of the accumulation of the second messenger (p)ppGpp (10–12).

We are interested in signal transduction by the essential second messenger nucleotide cyclic di-AMP (c-di-AMP). In *B. subtilis* and many other bacteria, this nucleotide plays a key role in the control of potassium homeostasis and osmoadaptation by binding to transporters for potassium and osmoprotective compounds as well as to proteins and RNA molecules that regulate the expression of the corresponding genes (13–15). In addition to these factors involved in ion and osmotic homeostasis, c-di-AMP can bind to target proteins that do not have any direct enzymatic, transport, or regulatory functions. The receptor protein DarA has been identified in *B. subtilis* and the related bacteria *Staphylococcus aureus* and *Listeria monocytogenes* (16–18). This protein belongs to the PII superfamily of regulatory proteins (19); however, its function so far has remained elusive. The DarB receptor protein is present in *B. subtilis* and *L. monocytogenes* but not in *S. aureus* (17, 20). This protein consists of two CBS domains (named after cystathionine beta-synthase) that together form a so-called Bateman domain. These Bateman domains can bind a variety of adenosine nucleotides, including AMP, ADP, ATP, S-adenosyl methionine, NAD, and c-di-AMP (17, 20, 21). In many bacteria, c-di-AMP is essential for growth on complex media (13, 22). In *B. subtilis*, c-di-AMP is even essential on minimal media in the presence of potassium or glutamate (23, 24). While the toxicity of potassium or glutamate can easily be overcome by the acquisition of suppressor mutations, this is not possible on complex media. However, the deletion of either *darA* or *darB* in a *B. subtilis* strain lacking c-di-AMP (Δdac) allows the emergence of suppressor mutations even on complex medium (24). This observation suggests that the DarA and DarB proteins are involved in harmful interactions in their c-di-AMP free apo-form. Indeed, the *B. subtilis* and *L. monocytogenes* DarB proteins can interact with the (p)ppGpp synthetase Rel in the absence of c-di-AMP and trigger the formation of (p)ppGpp and, thus, a stringent response (12, 25). c-di-AMP accumulates if the potassium levels in the cell are high, and the activation of Rel under conditions of potassium starvation links the availability of potassium, which is essential for ribosome function, to the stringent response and a global reprogramming of cellular activities.

Several studies have also implicated c-di-AMP signaling in the control of central metabolism. As mentioned above, c-di-AMP is essential if *B. subtilis* grows in the presence of glutamate, and the cellular c-di-AMP levels also respond to the presence of glutamate (24, 26). This glutamate toxicity at least partially results from activation of a low-affinity potassium transporter by glutamate and the very close interconnection between glutamate and potassium (2, 27). Moreover, in *L. monocytogenes* and in the lactic acid bacterium *Lactococcus lactis*, c-di-AMP binds to the pyruvate carboxylase and inhibits its enzymatic activity (17, 28, 29). By controlling the replenishment of the TCA cycle, c-di-AMP may play a major role in the regulation of cellular glutamate homeostasis.




FIG 1 DarB interacts with PC. (A) Initial pulldown experiment. *B. subtilis* crude extract was purified via a StrepTactin matrix and analyzed by mass spectrometry, and the identified peptides are shown. (B) *In vitro* pulldown experiment with PC. Purified PC protein was immobilized onto a StrepTactin column and incubated with DarB, DarB preincubated with *c*-di-AMP, or the control protein BSA. The presence of DarB and PC in the elution fractions was analyzed by Western blotting with antibodies against DarB and the His tag of PC. BSA served as a negative control. The elution fractions were further analyzed by mass spectrometry. (C) Specificity of interaction between PC and DarB. His-tagged YlxR (negative control) and DarB were bound to a Ni-NTA column, and cell extract of *B. subtilis* expressing Strep-tagged PC was then passed over the columns. The binding of the bait proteins was verified by Western blotting using antibodies raised against the His tag, and coelution of Strep-PC was tested using antibodies raised against the Strep tag. Abbreviations: MS, mass spectrometry; PSMs, peptide sequence matches; *cda*, *c*-di-AMP; M, marker; W, washing fraction; E, elution fraction.

In this work, we have serendipitously identified an interaction of the *c*-di-AMP target protein DarB with PC in *B. subtilis*. This interaction, which enhances the acetyl-coenzyme A (CoA)-dependent activation of PC activity, occurs with the apo-form of DarB, i.e., under conditions of potassium starvation if the cells experience a high demand for glutamate. While the molecular metabolism that links potassium availability and the intracellular *c*-di-AMP levels to PC activity are completely different in the closely related bacteria *B. subtilis* and *L. monocytogenes*, direct versus indirect with respect to *c*-di-AMP binding and positive or negative with respect to the effect on PC activity, they follow the same regulatory logic. As apo-DarB also triggers the stringent response by binding to Rel and, thus, the expression of the *pycA* gene encoding PC, *c*-di-AMP and DarB orchestrate the replenishment of the TCA cycle under conditions of potassium starvation at the levels of transcription and enzyme activity.

RESULTS

Identification of pyruvate carboxylase as an interaction partner of DarB. In addition to the recently described interaction of DarB with the dual-function (p)ppGpp synthetase/hydrolyase in *B. subtilis*, we serendipitously identified an interaction of DarB with pyruvate carboxylase (PC), a central metabolic enzyme that links glycolysis and the TCA cycle. This interaction was initially identified by passing a *B. subtilis* crude extract of cells grown in MSSM minimal medium over a StrepTactin column. PC and AccB, the biotin carboxyl carrier subunit of the acetyl-CoA carboxylase complex, contain biotin as a cofactor and, thus, intrinsically bind to the StrepTactin matrix. We analyzed the elution fractions for copurified proteins by mass spectrometry analysis (Fig. 1A). As expected, PC and AccB were identified with 155 and 9 peptide sequence matches (PSMs), respectively (Fig. 1A; see also Data Set S1A in the supplemental material). To our surprise, the DarB protein was the second highest-scoring protein, with 104 identified peptide sequence matches. In contrast to other coeluting proteins, DarB was not present in the washing fraction, indicating that its elution from the column was the result of an interaction with either PC or AccB. As the bait protein is usually identified with a higher number of PSMs than coeluting proteins, we assumed that DarB was bound to the column via PC rather than AccB, which was identified to a much lower extent.

To test the hypothesis that DarB interacts with pyruvate carboxylase, we assayed the binding of purified DarB to immobilized PC. For this, we purified the PC-6×His protein

from *E. coli* and biotinylated it *in vitro* with purified BirA^{Bsu} (Fig. S1A). Biotinylation of PC was verified via an avidin shift assay (Fig. S1B). For the pulldown, PC was coupled to a StrepTactin column, and DarB or YlxR, a control protein of similar size, was added. After extensive washing, the elution fractions were analyzed by Western blotting and mass spectrometry. Indeed, DarB was retained by and coeluted with PC (Fig. 1B and Fig. S2A and Data Set S1B). DarB was identified with 54 PSMs (Data Set S1B). In contrast, only 8 PSMs were found for the control protein YlxR. This result provides further evidence for the interaction between DarB and PC. To exclude the possibility of binding of DarB to the StrepTactin column, we passed biotinylated His-PC and DarB over the column and assayed the elution fractions for the presence of the proteins. As seen in prior experiments, His-PC was bound to the StrepTactin matrix whereas DarB was not (Fig. S2C), indicating that the elution of DarB depends on the presence of the interaction partner PC.

To get further evidence for the specific interaction between DarB and PC, we performed the interaction assay in an inverse fashion. For this purpose, His-tagged YlxR (as a negative-control protein) and DarB were bound to a nickel-nitrilotriacetic acid (Ni-NTA) column, and a cell extract of *B. subtilis* carrying the expression plasmid pGP1289 for constitutive expression of Strep-tagged PC was passed over the columns. The presence of the bait proteins and PC in the elution fractions was assayed by Western blotting using antibodies raised against the His or Strep tag, respectively. As shown in Fig. 1C, PC did not coelute with the control protein YlxR, whereas coelution was observed when DarB was bound to the matrix. Thus, DarB and PC specifically interact with each other.

DarB is a c-di-AMP receptor protein, and these proteins are considered to function in response to the presence of the ligand, and indeed we have shown previously that c-di-AMP prevents interaction of DarB with Rel (12). To study the importance of the second messenger c-di-AMP for the interaction of DarB with PC, we also tested the ability of DarB to bind PC in the presence of c-di-AMP in the pulldown assay described above. As observed for Rel, DarB bound PC to a much lesser extent (18 PSMs) in the presence of the second messenger, indicating that the presence of c-di-AMP reduces the interaction (Fig. 1B and Fig. S2A, Data set S1B).

Taken together, our results demonstrate a specific interaction between PC and the apo form of DarB. In contrast, the presence of c-di-AMP interferes with the interaction between the two proteins.

DarB interacts with the C-terminal part of PC. Pyruvate carboxylase is a multifunctional tetrameric protein composed of three functional domains, the N-terminal biotin carboxylase (BC), the central carboxyl transferase (CT), and the C-terminal biotin carboxyl carrier protein (BCCP) domains (Fig. 2A). To identify the PC domain that is responsible for the interaction with DarB, we generated and purified a truncated PC protein in which we deleted the BC domain (Fig. 2B). The ability of this truncated protein consisting of the CT and BCCP domains to interact with DarB was then tested again in the pulldown assay. Deletion of the BC domain did not prevent the interaction, as DarB still coelutes with the truncated PC (Fig. 2C and Fig. S2B and Data Set S1C). This indicates that DarB binds to the C-terminal part of PC, whereas the BC domain is not involved in the interaction with DarB. Interestingly, PC^{Lmo} binds c-di-AMP at the CT domain to inhibit the enzymatic activity (17).

PC does not bind c-di-AMP. In some bacteria, including *L. monocytogenes* and *L. lactis*, the pyruvate carboxylase is subject to regulation by c-di-AMP (17, 28). Thus, we wondered whether the *B. subtilis* enzyme would also directly interact with the second messenger. To study this, we expressed PC and the c-di-AMP target KdpD^{Lmo} as a positive control in *E. coli*, and the lysates of strains carrying the corresponding plasmids were assessed for a possible interaction with c-di-AMP using the differential radial capillary action of ligand assay (DRaCALA). While c-di-AMP clearly bound to the known target protein KdpD (30), no binding of the second messenger to PC was observed (Fig. S3).

Our results demonstrate that c-di-AMP does not directly bind to PC, unlike PC from other bacteria, such as *L. monocytogenes* and *L. lactis* (17, 28). Instead, the second messenger affects the protein-protein interaction between DarB and PC. This suggests that c-di-AMP-mediated control of pyruvate carboxylase activity is achieved in a distinct way in *B. subtilis*.

DarB is an activator of PC. Based on the results presented above, we hypothesized that in *B. subtilis*, PC activity might be regulated by the c-di-AMP receptor DarB rather than




FIG 2 DarB interacts with the C-terminal part of PC. (A) Domain organization of pyruvate carboxylase. An asterisk indicates the binding sites for acetyl-CoA (33). (B) Domain organization of the CT+BCCP mutant. (C) *In vitro* pulldown experiment with PC^{CT+BCCP}. Purified PC^{CT+BCCP} protein was immobilized onto a StrepTactin column and incubated with DarB or the control protein, BSA. The presence of DarB and PC in the elution fractions was analyzed by Western blotting with antibodies against DarB and the His tag of PC. BSA served as a negative control. The elution fractions were further analyzed by mass spectrometry. Abbreviations: BC, biotin carboxylation domain; PT, PC tetramerization domain; CT, carboxyltransferase domain; BCCP, biotin carboxyl carrier protein; E, elution fraction; W, wash fraction.

directly by *c*-di-AMP, as described for *L. monocytogenes* and *L. lactis* (17, 28). To test this idea, we used purified PC to assay the formation of oxaloacetate.

The purified PC behaved similarly to published data in a malate dehydrogenase-coupled standard spectrophotometric assay in the presence of acetyl-CoA as the known effector metabolite (31). We determined a K_m for pyruvate of 0.23 mM (Fig. 3A). Interestingly, the substrate affinity was not altered in the presence of DarB (0.23 mM) (Fig. 3A). We measured a V_{max} of 42.7 and 87.9 U·mg protein⁻¹ for PC in the absence and presence of DarB, respectively (Fig. 3A). Typically, allosteric enzyme activators affect only one of the two Michaelis-Menten parameters and either lower the K_m or raise the V_{max} . Thus, DarB seems to act as an activator of PC, as its presence increases the V_{max} 2-fold. The presence of the control protein bovine serum albumin (BSA) does not affect the enzymatic activity of PC, indicating that the increase in the V_{max} in the presence of DarB is specific.

The carboxylation of pyruvate serves to generate one of the two substrates for citrate synthesis. The second substrate, acetyl-CoA, is an allosteric activator of PC (32, 33). PC proteins from different bacteria show different levels of acetyl-CoA dependence. While the catalytic activity of *L. lactis* PC is not affected by acetyl-CoA (28), it plays a significant role in the activation of the enzyme in *B. subtilis*, *L. monocytogenes*, and *Rhodobacter capsulatus* (17, 34, 35). We asked whether acetyl-CoA and DarB exert their effects on PC independently or whether they act in a coordinated manner. To address this question, we determined PC activity in the presence of various acetyl-CoA concentrations (Fig. 3B). As described previously (34), the activity of PC was strongly enhanced in the presence of acetyl-CoA. In the absence of acetyl-CoA, DarB did not affect PC activity, whereas the acetyl-CoA-dependent activation of the enzymatic activity was further enhanced if DarB was present. In contrast, BSA, which served as a control protein, did not affect PC activity irrespective of the availability of acetyl-CoA. Thus, the data indicate that DarB functions as a coactivator of PC activity. To get a deeper insight into this observation, we repeated the pulldown experiments in the presence of acetyl-CoA. Indeed, the presence of acetyl-CoA increased the amount of DarB retained on the column by immobilized PC (Fig. 3C). This enhanced interaction between the two proteins in the presence of acetyl-CoA may explain the cumulative activation of PC activity by both acetyl-CoA and DarB.

The data presented above show that *c*-di-AMP interferes with the interaction of DarB with PC (Fig. 1B). We therefore also tested the effect of the second messenger on the activation of




FIG 3 DarB stimulates the synthesis of oxaloacetate. The activity of PC was assessed in an *in vitro* activity assay. (A) The reaction mix contained 0.26 μ M PC, 2.6 μ M DarB/BSA/DarB^{L38F} (measured based on monomer), 100 μ M acetyl-CoA, 2 mM ATP, 25 mM KHCO₃, and the indicated pyruvate concentrations. The catalytic activity of PC toward pyruvate obeys Michaelis-Menten kinetics. (B) PC is activated by acetyl-CoA and DarB, and activation by DarB is acetyl-CoA dependent. The reaction mix contained 0.26 μ M PC and 2.6 μ M DarB/BSA/DarB^{L38F}, 25 mM KHCO₃, 2.5 mM pyruvate, and various acetyl-CoA concentrations. (C) *c*-di-AMP inhibits activation by DarB to 16%. *cdA* itself has no influence on PC. The reaction mix contained 0.26 μ M PC, 2.6 μ M DarB, 25 mM KHCO₃, 2.5 mM pyruvate, 100 μ M acetyl-CoA, and 26 μ M *cdA* if indicated. The experiment was conducted with $n = 3$ biologically independent samples. (D) *c*-di-AMP inhibits activation by DarB to 16%. *cdA* itself has no influence on PC. The reaction mix contained 0.26 μ M PC, 2.6 μ M DarB, 25 mM KHCO₃, 2.5 mM pyruvate, 100 μ M acetyl-CoA, and 26 μ M *cdA* if indicated. Data are presented as mean values \pm standard deviations. Statistical analysis was performed using a one-way analysis of variance, followed by Tukey's multiple-comparison test (****, $P < 0.0001$). *cdA*, *c*-di-AMP.

PC by DarB. As shown in Fig. 3D, the presence of *c*-di-AMP reduces the activation of PC by DarB. In agreement with the results from the DRaCALA experiments showing that PC is unable to bind *c*-di-AMP (Fig. S3), the presence of the second messenger alone did not affect PC activity (Fig. 3D), demonstrating that the decrease in activation is mediated by *c*-di-AMP binding to DarB.

DarB is unable to overcome the inhibition of PC by aspartate. In addition to the activation by acetyl-CoA, PC is subject to allosteric inhibition by aspartate (36). Aspartate functions as a regulatory feedback inhibitor that responds to increased levels of TCA cycle intermediates. As aspartate was previously shown to inhibit the enzyme competitively with respect to acetyl-CoA (36), we asked whether aspartate might also interfere with the activation by DarB. PC assays demonstrated that DarB was no longer able to activate PC in the presence of aspartate (Fig. S4).

Differential effects of a mutation in the interaction surface of DarB on the interaction with PC. To further validate the regulatory interaction of DarB with PC, we mutated the DarB protein at its interaction surface (12, 25) (PDB entry 6YJA). Specifically, we changed Leu38 to Phe. DarB^{L38F} was tested for *c*-di-AMP binding interaction with the known DarB target proteins, Rel and PC, for its effect on PC activity and for binding of acetyl-CoA. Isothermal titration calorimetry (ITC) revealed that the mutant protein binds *c*-di-AMP with a similar affinity as the wild-type protein (Fig. S5A), indicating that it folds correctly. To verify that the L38F mutation is located at the interaction surface, we tested the ability of the DarB mutant to bind to its initially identified interaction partner, the Rel protein. We observed that the L38F mutation




FIG 4 DarB affects the synthesis of amino acids derived from oxaloacetate. Determination of intracellular metabolite levels in the wild type, a *darB* mutant, and a strain overexpressing *darB* by GC-MS. The metabolites were quantified relative to the wild type. The experiments were performed with three biological replicates. (A) Determination of oxaloacetate in derivatives of the wild-type strain 168 and of the *citZ* mutant lacking citrate synthase. (B) Determination of intracellular levels of the oxaloacetate-derived amino acids aspartate and threonine. EV, empty vector control.

abolished the ability to bind Rel, whereas the wild-type DarB protein efficiently bound Rel (Fig. S5B). Thus, the mutant protein folds correctly but has lost the ability to interact with the Rel protein, confirming that the mutation affects the interaction surface of DarB. To investigate whether the interaction with PC is also affected by the mutation, we tested the ability of the mutant protein to interact with PC in the *in vitro* pull-down experiment. Surprisingly, the mutant protein was still able to bind to PC in the pull-down experiment (Fig. S5C), suggesting that the single L38F amino acid exchange is not sufficient to abolish the interaction. However, when we tested the DarB^{L38F} mutant protein in the activity assay, we observed that it is unable to activate PC (Fig. 3A and B). This counterintuitive result suggests that highly specific interactions between particular residues of the two proteins are required for the activation of PC.

Overexpression of DarB results in *in vivo* changes in metabolite concentration.

The data presented above suggest that the interaction of DarB with PC results in an increase of the intracellular oxaloacetate levels. To verify this assumption, we compared the intracellular oxaloacetate concentrations in a wild-type strain, the *darB* mutant, and the *darB*⁺ strain overexpressing DarB. Due to the high activity of citrate synthase, freshly synthesized oxaloacetate is quickly metabolized to citrate. To allow accumulation of oxaloacetate, we performed these measurements in a *citZ* mutant strain that lacks citrate synthase and is therefore unable to use oxaloacetate for citrate synthesis. However, the levels of oxaloacetate were still close to the detection limit (Fig. 4A). A previous study suggested that the effect of increased expression of *pycA* could only be detected by measuring the accumulation of the oxaloacetate-derived amino acids aspartate and threonine (10). Indeed, the levels of these amino acids were increased in the *darB* overexpression strain (Fig. 4B). In contrast, the deletion of *darB* set their

relative levels back to the wild-type situation. These findings support the conclusion that DarB activates PC activity.

DISCUSSION

The data presented in this study identify the c-di-AMP receptor protein DarB as a bona fide activator of PC. The interaction between the two proteins enhances enzyme velocity in the presence of the known allosteric activator acetyl-CoA. This additional activation of PC ensures that the TCA cycle can operate even under conditions of high demand for specific intermediates. Under most circumstances, the withdrawal of intermediates for anabolic purposes is rather constant; however, under conditions of potassium starvation a substantial part of the 2-oxoglutarate formed in the TCA cycle is needed to produce glutamate as the precursor for positively charged amino acids that replace potassium in buffering the negative charge of DNA (4). Thus, it is important to couple the replenishment of the TCA cycle to potassium availability.

The control of the anaplerotic reaction catalyzed by PC is achieved by the c-di-AMP receptor protein DarB in *B. subtilis*. Under conditions of potassium starvation, the c-di-AMP level is low, and apo-DarB binds and activates PC, allowing replenishment of TCA cycle intermediates under conditions of high demand. Interestingly, c-di-AMP also controls PC activity in *L. monocytogenes* and *L. lactis*. However, unlike what was observed here for *B. subtilis*, in those bacteria, c-di-AMP, which accumulates if the potassium supply is sufficient (23), directly binds to PC and inactivates the enzyme (17, 28). Even though the exact mechanism of regulation differs between species, the outcome, higher PC activity in the absence of potassium, is the same.

The presence of c-di-AMP interferes with the interaction between DarB and PC and, thus, with PC activation. It is interesting that the recently determined structure of DarB in the presence of c-di-AMP (PDB entry 6YJA) suggests that one adenine of the bound c-di-AMP is buried in the DarB dimer interface, whereas the second adenine protrudes out of the protein. This immediately suggests that this protruding adenine prevents DarB binding to PC in a sting-like manner.

B. subtilis strains lacking c-di-AMP are unable to grow on complex medium. Such strains can acquire suppressor mutations that allow growth on complex medium only in the absence of either of the c-di-AMP-binding signal transduction proteins, DarA or DarB (24). This observation suggests that apo-DarA and apo-DarB are engaged in growth inhibiting interactions under these conditions. Indeed, the activation of PC by apo-DarB might fuel a futile cycle and result in the loss of energy as the reaction requires the hydrolysis of ATP. In complex medium, cells have all amino acids in excess, so the DarB-mediated wasteful activation of PC as well as of the Rel protein is indeed likely to result in growth inhibition.

The results reported here and in previous studies establish that DarB modulates the activities of at least two enzymes under conditions of potassium limitation: DarB activates Rel (12, 25), resulting in the accumulation of (p)ppGpp and an induction of the stringent response. A part of this response is the increased expression of the *pycA* gene encoding PC. Thus, DarB regulates pyruvate carboxylation at two levels, i.e., (i) directly at the protein level by binding to the enzyme and stimulating the synthesis of oxaloacetate and (ii) indirectly by interaction with Rel, which leads to activation of the stringent response and to the increased expression of the *pycA* gene (Fig. 5). This double activation of PC faithfully ensures the production of oxaloacetate and, thus, the continued operation of the TCA cycle, the core of *B. subtilis* metabolism, under conditions of potassium starvation. The control of one biological process by a signaling molecule that binds different targets to regulate multiple steps of the process has been termed sustained sensing (37). In this case, c-di-AMP controls DarB in a negative manner for both its activities, and the regulatory interactions between DarB and Rel or PC are inhibited by c-di-AMP during growth under potassium-sufficient conditions. This may also explain why these regulatory processes have not been discovered earlier. The regulation of pyruvate carboxylase is the second example of c-di-AMP-mediated sustained sensing in *B. subtilis* in addition to the control of potassium homeostasis by direct binding of c-di-AMP to potassium transporters and riboswitches that control their expression (20, 23)




FIG 5 Control of PC activity by DarB follows the model of sustained sensing. DarB regulates the activity of PC at two stages: (i) by direct binding to the enzyme and activation and (ii) indirectly by activation of the stringent response and increased expression of the *pycA* transcript resulting from the interaction with the (p)ppGpp synthetase/hydrolase Rel.

(Fig. 5). It will be interesting to test whether other *c*-di-AMP-controlled processes, such as the uptake of osmoprotective compounds (14, 20, 38, 39), are also subject to dual control of gene expression and protein activity.

A striking feature of *c*-di-AMP signaling via dedicated signal transduction proteins is that the interactions take place between the apo-proteins and their partners. For both DarA and DarB, a growth-inhibitory effect on complex medium has been observed in *B. subtilis* and *L. monocytogenes* if the cells are unable to produce *c*-di-AMP (24, 40), indicating that the apo-proteins are involved in interactions. Moreover, two interaction partners have so far been discovered for DarB: this protein binds to the Rel protein in both *B. subtilis* and *L. monocytogenes* (12, 25), and, as described in this study, *B. subtilis* DarB also interacts with PC. In both cases, binding of apo-DarB, which is present under conditions of potassium starvation, controls the activities of the partner proteins. In principle, the control of the DarB partner in response to potassium starvation could also occur by binding of *c*-di-AMP, resulting in the inactivation of the target protein. Indeed, this was observed for PC of *L. monocytogenes* and *L. lactis* (17, 28). Alternatively, the *c*-di-AMP-bound receptor proteins might interact with their targets to inactivate them. Of the three scenarios, interaction of the apo *c*-di-AMP receptors with their targets might be preferred, since the evolution of protein interaction surfaces may have fewer constraints than the evolution of second-messenger binding pockets that require binding under standard conditions (potassium sufficiency). Strikingly, in cyanobacteria, the *c*-di-AMP receptor protein SbtB binds and activates its target, GlgB, an enzyme required for glycogen synthesis in the *c*-di-AMP-bound state (41). It will be interesting to see whether future research will discover DarB targets that interact with the *c*-di-AMP-bound form of DarB and whether, for the other *c*-di-AMP binding signal transduction proteins, the interactions also occur with the apo-proteins.

MATERIALS AND METHODS

Strains, media, and growth conditions. *E. coli* DH5 α and Rosetta(DE3) (42) were used for cloning and for the expression of recombinant proteins, respectively. All *B. subtilis* strains used in this study are derivatives of the laboratory strain 168. *B. subtilis* and *E. coli* were grown in Luria-Bertani (LB) or in sporulation (SP) medium (42, 43). For growth assays and the *in vivo* interaction experiments, *B. subtilis* was cultivated in LB or MSSM (23). MSSM is a modified SM medium in which KH₂PO₄ was replaced by NaH₂PO₄ and KCl was added as indicated. The media were supplemented with ampicillin (100 μ g/ml), kanamycin (50 μ g/ml), chloramphenicol (5 μ g/ml), or erythromycin and lincomycin (2 and 25 μ g/ml, respectively) if required.

DNA manipulation. Transformation of *E. coli* and plasmid DNA extraction were performed using standard procedures (42). All commercially available plasmids, restriction enzymes, T4 DNA ligase, and DNA polymerases were used as recommended by the manufacturers. *B. subtilis* was transformed with plasmids, genomic DNA, or PCR products according to the two-step protocol (43). Transformants were selected on LB plates containing erythromycin (2 $\mu\text{g/ml}$) plus lincomycin (25 $\mu\text{g/ml}$), chloramphenicol (5 $\mu\text{g/ml}$), kanamycin (10 $\mu\text{g/ml}$), or spectinomycin (250 $\mu\text{g/ml}$). DNA fragments were purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany). DNA sequences were determined by the dideoxy chain termination method (42). Introduction of mutations in the *darB* allele was achieved by the combined chain reaction by using an additional 5' phosphorylated primer to introduce the mutation (44).

Construction of mutant strains by allelic replacement. Deletion of the *citZ* gene was achieved by transformation of *B. subtilis* 168 with a PCR product constructed using oligonucleotides to amplify DNA fragments flanking the target genes and an appropriate intervening resistance cassette as described previously (45). The integrity of the regions flanking the integrated resistance cassette was verified by sequencing PCR products of about 1,100 bp amplified from chromosomal DNA of the resulting mutant strains, GP797. All strains and oligonucleotides are listed in Tables S1 and S3, respectively, in the supplemental material.

Plasmid constructions. The *pycA*, *darB-L38F*, and *ylxR* alleles were amplified using chromosomal DNA of *B. subtilis* 168 as the template and appropriate oligonucleotides that attached specific restriction sites to the fragment. Those were XbaI and XhoI for cloning *pycA* in pET28a (Novagen, Germany) and BsaI and XhoI for cloning *darB-L38F* and *ylxR* in pET-SUMO (Invitrogen, Germany). The truncated *pycA* variants were constructed as follows. *pycA*^{CT+BCCP} contained amino acids 461 to 1148 and was cloned into pET28a by adding XbaI and XhoI restriction sites. For purification of Strep-PC from *B. subtilis* extracts, the *pycA* gene was cloned between the XbaI and SphI restriction sites of pGP380 (46). The *B. subtilis* *birA* gene was amplified and the PCR product was cloned between the BamHI and Sall sites of the expression vector pWH844 (47). All plasmids are listed in Table S2.

Protein expression and purification. *E. coli* Rosetta(DE3) was transformed with the plasmid pGP2972, pGP3481, pGP3618, pGP3458, pGP3455, or pGP2690, encoding wild-type or mutant 6 \times His-SUMO-DarB for purification of DarB, DarB^{L38F}, YlxR, wild-type and truncated PC-6 \times His and PC^{CT+BCCP}-6 \times His, or BirA. For overexpression of DarB, DarB^{L38F}, YlxR, and BirA, cells were grown in 2 \times LB, and expression was induced by the addition of isopropyl 1-thio- β -D-galactopyranoside (IPTG; final concentration, 1 mM) to exponentially growing cultures (optical density at 600 nm [OD₆₀₀] of 0.8). The His-tagged proteins DarB, DarB^{L38F}, YlxR, and BirA were purified in 1 \times ZAP buffer (50 mM Tris-HCl, 200 mM NaCl, pH 7.5 [pH 8.3 for 6 \times His-BirA]). Cells were lysed by four passes (18,000 lb/in²) through an HTU DIGI-F press (G. Heinemann, Germany). After lysis, the crude extract was centrifuged at 46,400 \times g for 60 min and then passed over a Ni²⁺ nitrilotriacetic acid column (IBA, Göttingen, Germany). The proteins were eluted with an imidazole gradient. After elution, the fractions were tested for the desired protein using SDS-PAGE. For the purification of BirA, the column was washed with two column volumes of 4 M LiCl to remove DNA prior to elution of the protein with 20 mM and 100 mM imidazole. BirA was dialyzed against 1 \times ZAP buffer (pH 8.3, 5% glycerol). To remove the SUMO tag from the 6 \times His-SUMO-tagged proteins, the relevant fractions were combined, and the SUMO tag was removed with the SUMO protease (ratio, 100:1) during overnight dialysis against 1 \times ZAP buffer (pH 7.5). The cleaved SUMO moiety and the protease were removed using a Ni²⁺ nitrilotriacetic acid column (IBA), and the proteins were dialyzed against 1 \times ZAP buffer (pH 7.5).

PC was overexpressed in *E. coli* Rosetta(DE3) cultures carrying the plasmids encoding wild-type and the truncated PC in 2 \times LB at 37°C. When the cultures reached an OD₆₀₀ of 1.2, MnCl₂ was added (final concentration, 10 mM) and the cultures were transferred to 28°C. After 20 min, expression of the recombinant proteins was induced by the addition of isopropyl 1-thio- β -D-galactopyranoside (final concentration, 0.3 mM), and the cultures were grown for 3 h. PC-6 \times His and PC^{CT+BCCP}-6 \times His were purified as described previously (48) in buffer A (20 mM Tris, pH 7.8, 200 mM NaCl, 0.5 mM EGTA, 6 mM β -mercaptoethanol). The cells were lysed and purified as described above. PC and PC^{CT+BCCP} were dialyzed against dialysis buffer (10 mM Tris, pH 7.8, 150 mM KCl, 6 mM β -mercaptoethanol, 5% glycerol). The purified proteins were concentrated in a Vivaspin turbo 15 (Sartorius) centrifugal filter device (cutoff of 5 or 50 kDa). The protein samples were stored at -80°C until further use. The protein concentration was determined according to the method of Bradford (49) using the Bio-Rad dye binding assay and bovine serum albumin as the standard.

Biotinylation of PC and PC^{CT+BCCP}. Biotinylation of PC and PC^{CT+BCCP} was achieved by incubation of PC (25 μM) with purified BirA (50 μM) in 1 \times ZAP buffer (pH 8.3) containing 2 mM ATP, 5 mM MgCl₂, and 0.15 mM biotin. The reaction mixture was incubated overnight in the fridge, and biotinylation of the protein was tested with an avidin shift assay. For this purpose, 4 μl of the reaction mixture together with SDS-loading dye were boiled for 5 min at 95°C. Afterwards, 36 μl avidin (1.2 mg/ml) was added and the sample was incubated at 25°C for 40 min. A sample with buffer instead of avidin served as a control. Binding of avidin to the biotinylated PC was visualized via an SDS-PAGE. The interaction between avidin and biotin is strong enough to be stable under denaturing conditions. Proper biotinylation of PC will result in a complete shift on the gel. After confirming the biotinylation, PC was dialyzed against dialysis buffer to remove excess biotin. To yield pure biotinylated PC protein, the protein was purified via a StrepTactin column (IBA, Göttingen, Germany). Therefore, the column was washed with dialysis buffer until the wash fraction appeared clear and PC was eluted with 7 mM biotin. The eluates were pooled and dialyzed one last time against dialysis buffer. The protein was concentrated in a Vivaspin turbo 15 (Sartorius) centrifugal filter device (cutoff, 50 kDa) and stored at -80°C until further use.

Initial pulldown for identification of potential binding partners. To identify potential binding partners of PC, *B. subtilis* was cultivated in 250 ml MSSM medium containing glutamate as the sole nitrogen source and 5 mM potassium chloride until exponential growth phase was reached (OD₆₀₀ ~0.4 to

0.6). The cells were harvested immediately and stored at -20°C . Naturally biotinylated proteins and their potential interaction partners were then purified from crude extracts using a StrepTactin column (IBA, Göttingen, Germany) and desthiobiotin (2.5 mM) as the eluent. The eluted proteins were analyzed by mass spectrometry analysis.

In vitro analysis of protein-protein interactions. To study the interaction between DarB and PC, *E. coli* Rosetta(DE3) was transformed with pGP2972(6 \times His-SUMO-DarB), pGP3481(6 \times His-SUMO-DarB^{L38F}), pGP3618(6 \times His-SUMO-YlxR), pGP3458(PC-6 \times His), or pGP3455(PC^{CT+BCCP}-6 \times His), and the proteins were overexpressed as described above; 250 μl of StrepTactin (IBA, Göttingen, Germany) matrix was equilibrated and loaded with 2 nmol PC and 15 nmol DarB (if stated preincubated 30 min with c-di-AMP [150 nmol]) or 15 nmol YlxR, respectively. Incubation happened overnight at 4°C under constant rotation. Purification was continued by extensive washing of the column with dialysis buffer before PC, together with binding partners, was eluted with biotin (7 mM). The elution fractions were analyzed by Western blotting (50) using antibodies against the His tag (1:1,000) or DarB (1:10,000), respectively, silver staining, and mass spectrometry.

Protein identification by mass spectrometry and data analysis. The elution fractions of the pull-down experiments were analyzed by mass spectrometry. For this purpose, the respective samples were separated on a polyacrylamide gel, the respective bands were excised, and the peptides were digested and extracted from the gel pieces and purified using C₁₈ stop and go extraction (STAGE) tips as described previously (12, 51–53). The peptides were separated by reverse-phase liquid chromatography using an RSLCnano Ultimate 3000 system (Thermo Fisher Scientific). Peptides were loaded on an Acclaim PepMap 100 precolumn (100 μm by 2 cm, C₁₈, 3 μm , 100 Å; Thermo Fisher Scientific) with 0.07% trifluoroacetic acid. Analytical separation of peptides was done using an Acclaim PepMap RSLC column (75 μm by 50 cm, C₁₈, 3 μm , 100 Å; Thermo Fisher Scientific) running a water-acetonitrile gradient at a flow rate of 300 nL/min. Chromatographically eluting peptides were online ionized by nano-electrospray ionization (nESI) with a Nanospray flex ion source (Thermo Scientific) and continuously transferred into the mass spectrometer Q Exactive HF (Thermo Scientific). Full scans in a mass range of 300 to 1,650 m/z were recorded at a resolution of 30,000, followed by data-dependent top 10 HCD fragmentation at a resolution of 15,000 (dynamic exclusion enabled). Liquid chromatography-mass spectrometry (LC-MS) method programming and data acquisition were performed with XCalibur software 4.0 (Thermo Fisher Scientific). MS/MS data were searched against a *B. subtilis*-specific protein database (UniProt Proteome ID UP000001570) using the Proteome Discoverer Software 2.2. The digestion mode was trypsin/P, and the maximum number of missed cleavage sites was set to two. Carbamidomethyl at cysteines was set as a fixed modification, and oxidation at methionines and N-terminal acetylation of proteins were variable modifications. Mass tolerances of precursors and fragment ions were 10 ppm and 20 ppm, respectively. False discovery rates were calculated using the reverse decoy mode, and the filter for peptide spectrum matches was set to 0.01.

Isothermal titration calorimetry. ITC experiments were carried out with a VP-ITC microcalorimeter (MicroCal Inc., Northampton, MA) to determine the affinity of DarB to c-di-AMP or Rel^{NTP}. In a typical setup, DarB (10 μM) was placed in the sample cell, and c-di-AMP (100 μM in the same buffer) was placed in the titration syringe. All experiments were carried out at 20°C with a stirring speed of 329 rpm. The parameters used for the titration series are given in Table S4. Data analysis was carried out using MicroCal PEQ-ITC analysis software (MalvernPanalytical).

Kinetic studies. The catalytic activity of PC was assessed by coupling the production of oxaloacetate to the oxidation of NADH by malate dehydrogenase, which can be monitored spectrophotometrically by the decrease in absorbance at 340 nm. The activity was measured at 25°C in a reaction mixture containing 0.26 μM PC, 2.6 μM DarB, DarB^{L38F} or BSA (based on monomer), 10 mM Tris (pH 7.8), 150 mM KCl, 5 mM MgCl₂, 10 U malate dehydrogenase, 0.4 mM NADH, 25 mM KHCO₃, 2.5 mM pyruvate, 2 mM ATP, and 100 μM acetyl-CoA, if not stated otherwise. The reaction was started with addition of the substrates.

Determination of intracellular amino acid and organic acid pools. Intracellular metabolite levels of *B. subtilis* cells were determined by GC-MS. Bacterial cells were cultivated in LB medium until exponential growth phase; 40 ml of each culture was harvested by filtration (54). The filter was washed three times with 0.6% NaCl and transferred into 4 ml extraction solution (60% ethanol) and stored overnight at -20°C . *Allo*-inositol was used as the internal standard. Metabolites were extracted as described previously (55). Samples were dried under nitrogen stream and then extracted with 1 ml of extraction buffer (methanol-chloroform-water, 32.25:12.5:6.25 [vol/vol/vol]). To induce phase separation, 500 μl water was added and samples were taken for derivatization from the upper polar fraction. For metabolites of low abundance, 200 μl of the upper phase was evaporated under nitrogen stream while 10 μl was used for metabolites of high abundance. The evaporated samples were derivatized with 15 μl methoxyamine hydrochloride and 30 μl N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) as described previously (56) to transform the metabolites into their methoxyimino (MEOX) and trimethylsilyl (TMS) derivatives. Samples of low-abundance metabolites were measured with a split of 1:5, and high-abundance metabolite samples were measured with a split of 1:2. GC-MS measurements were performed as described previously (57). If the metabolites were not identified by an external standard, the spectra were identified with the Golm metabolome database (GMD) and the National Institute of Standards and Technology (NIST) spectral library 2.0f. The chemical information on metabolites identified with the GMD can be obtained at <http://gmd.mpimp-golm.mpg.de/search.aspx> (58). Data were analyzed using MSD ChemStation (F.01.03.2357). The data were analyzed by relative quantification. The average of the wild type was set to 1, and all data were normalized to that. Values between 0 and 1 indicate lower relative abundance and values larger than 1 higher abundance compared to wild-type levels.

Identification of c-di-AMP-binding proteins by DRaCALA. The expression of the proteins upon induction with IPTG (final concentration, 0.1 mM) was verified by SDS-PAGE. ³²P-labeled c-di-AMP synthesis

was performed using purified diadenylate cyclase DisA (18). The protein-ligand interaction experiment was performed using *E. coli* whole-cell lysates, which were either induced by the addition of IPTG (final concentration, 1 mM) overnight or in 1:50 subculture as described previously (59, 60). All binding reactions were performed in 1 × binding buffer (10 mM Tris, pH 8, 100 mM NaCl, 5 mM MgCl₂) containing ~10 pM ³²P-labeled c-di-AMP. Protein-ligand mixtures were spotted on nitrocellulose membrane (Amersham Hybond-ECL; GE Healthcare) and dried. The areas and intensities of the spots were quantified by exposing phosphorimager screens and scanning by a FUJI FLA-7000 phosphorimager. The competition assays were performed with 100 μM unlabeled ATP and the absence or presence of 100 μM unlabeled c-di-AMP (Axxora).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

DATA SET S1, PDF file, 0.2 MB.

FIG S1, PDF file, 0.5 MB.

FIG S2, PDF file, 0.6 MB.

FIG S3, PDF file, 0.6 MB.

FIG S4, PDF file, 0.5 MB.

FIG S5, PDF file, 0.6 MB.

TABLE S1, PDF file, 0.1 MB.

TABLE S2, PDF file, 0.1 MB.

TABLE S3, PDF file, 0.1 MB.

TABLE S4, PDF file, 0.04 MB.

ACKNOWLEDGMENTS

This work was supported by grants of the Deutsche Forschungsgemeinschaft (DFG) within the Priority Program SPP1879 (Stu 214-16) (to J.S.). The funders had no role in study design, data collection, analysis and interpretation, decision to submit the work for publication, or preparation of the manuscript.

We thank Anika Klewing and Jan Gundlach for their help with the construction of strains and plasmids, respectively. We are grateful to Achim Dickmanns for his support with the ITC experiments. Achim Dickmanns and Piotr Neumann are acknowledged for helpful discussions. We also thank Oliver Valerius for the help with LC-MS analyses, which were done at the Service Unit LCMS Protein Analytics of the Göttingen Center for Molecular Biosciences (GZMB) at the Georg-August-University Göttingen (grant DFG-GZ: INST 186/1230-1 FUGG to S.P.). A.P. and R.D. are acknowledged for the genome sequencing.

Author contributions: study design, L.K. and J.S.; experimental work, L.K., C.H., D.W., P.S., K.S., A.T., V.T.L., and T.I.; data analysis, L.K., C.H., K.S., V.T.L., T.I., and J.S; manuscript writing, L.K., K.S., V.T.L., and J.S.

REFERENCES

- Bennett BD, Kimball EH, Gao M, Osterhout R, van Dien SJ, Rabinowitz JD. 2009. Absolute metabolite concentrations and implied enzyme active site occupancy in *Escherichia coli*. *Nat Chem Biol* 5:593–599. <https://doi.org/10.1038/nchembio.186>.
- Gundlach J, Commichau FM, Stülke J. 2018. Of ions and messengers: an intricate link between potassium, glutamate, and cyclic di-AMP. *Curr Genet* 64:191–195. <https://doi.org/10.1007/s00294-017-0734-3>.
- Bremer E, Krämer R. 2019. Responses of microorganisms to osmotic stress. *Annu Rev Microbiol* 73:313–334. <https://doi.org/10.1146/annurev-micro-020518-115504>.
- Gundlach J, Herzberg C, Hertel D, Thürmer A, Daniel R, Link H, Stülke J. 2017. Adaptation of *Bacillus subtilis* to life at extreme potassium limitation. *mBio* 8:e00861-17. <https://doi.org/10.1128/mBio.00861-17>.
- Jourlin-Castelli C, Mani N, Nakano MM, Sonenshein AL. 2000. CcpC, a novel regulator of the LysR family required for glucose repression of the *citB* gene in *Bacillus subtilis*. *J Mol Biol* 295:865–878. <https://doi.org/10.1006/jmbi.1999.3420>.
- Blencke HM, Reif I, Commichau FM, Detsch C, Wacker I, Ludwig H, Stülke J. 2006. Regulation of *citB* expression in *Bacillus subtilis*: integration of multiple metabolic signals in the citrate pool and by the general nitrogen regulatory system. *Arch Microbiol* 185:136–146. <https://doi.org/10.1007/s00203-005-0078-0>.
- Pechter KP, Meyer FM, Serio AW, Stülke J, Sonenshein L. 2013. Two roles for aconitase in the regulation of tricarboxylic acid branch gene expression in *Bacillus subtilis*. *J Bacteriol* 195:1525–1537. <https://doi.org/10.1128/JB.01690-12>.
- Meyer FM, Gerwig J, Hammer E, Herzberg C, Commichau FM, Völker U, Stülke J. 2011. Physical interactions between tricarboxylic acid cycle enzymes in *Bacillus subtilis*: evidence for a metabolon. *Metab Eng* 13: 18–27. <https://doi.org/10.1016/j.ymben.2010.10.001>.
- Bartholomae M, Meyer FM, Commichau FM, Burkovski A, Hillen W, Seidel G. 2014. Complex formation between malate dehydrogenase and isocitrate dehydrogenase from *Bacillus subtilis* is regulated by tricarboxylic acid cycle metabolites. *FEBS J* 281:1132–1143. <https://doi.org/10.1111/febs.12679>.
- Tojo S, Kumamoto K, Hirooka K, Fujita Y. 2010. Heavy involvement of stringent transcription control depending on the adenine or guanine species of the transcription initiation site in glucose and pyruvate metabolism in *Bacillus subtilis*. *J Bacteriol* 192:1573–1585. <https://doi.org/10.1128/JB.01394-09>.
- Bange G, Brodersen DE, Liuzzi A, Steinchen W. 2021. Two P or not two P: understanding regulation by the bacterial second messengers (p)ppGpp. *Annu Rev Microbiol* 75:383–406. <https://doi.org/10.1146/annurev-micro-042621-122343>.
- Krüger L, Herzberg C, Wicke D, Bähre H, Heidemann JL, Dickmanns A, Schmitt K, Ficner A, Stülke J. 2021. A meet-up of two second messengers:

- the c-di-AMP receptor DarB controls (p)ppGpp synthesis in *Bacillus subtilis*. *Nat Commun* 12:1210. <https://doi.org/10.1038/s41467-021-21306-0>.
13. Stülke J, Krüger L. 2020. Cyclic di-AMP signaling in bacteria. *Annu Rev Microbiol* 74:159–179. <https://doi.org/10.1146/annurev-micro-020518-115943>.
 14. Commichau FM, Gibhardt J, Halbedel S, Gundlach J, Stülke J. 2018. A delicate connection: c-di-AMP affects cell integrity by controlling osmolyte transport. *Trends Microbiol* 26:175–185. <https://doi.org/10.1016/j.tim.2017.09.003>.
 15. He J, Yin W, Galperin MY, Chou SH. 2020. Cyclic di-AMP, a second messenger of primary importance: tertiary structures and binding mechanisms. *Nucleic Acids Res* 48:2807–2829. <https://doi.org/10.1093/nar/gkaa112>.
 16. Gundlach J, Dickmanns A, Schröder-Tittmann K, Neumann P, Kaesler J, Kampf J, Herzberg C, Hammer E, Schwede F, Kaever V, Tittmann K, Stülke J, Ficner R. 2015. Identification, characterization, and structural analysis of the cyclic di-AMP-binding PII-like signal transduction protein DarA. *J Biol Chem* 290:3069–3080. <https://doi.org/10.1074/jbc.M114.619619>.
 17. Sureka K, Choi PH, Precit M, Delince M, Pensinger DA, Huynh TN, Jurado AR, Goo YA, Sadilek M, Iavarone AT, Sauer JD, Tong L, Woodward JJ. 2014. The cyclic dinucleotide c-di-AMP is an allosteric effector of metabolic enzyme function. *Cell* 158:1389–1401. <https://doi.org/10.1016/j.cell.2014.07.046>.
 18. Corrigan RM, Campeotto I, Jeganathan T, Roelofs KG, Lee VT, Gründling A. 2013. Systematic identification of conserved bacterial c-di-AMP receptor proteins. *Proc Natl Acad Sci U S A* 110:9084–9089. <https://doi.org/10.1073/pnas.1300595110>.
 19. Forchhammer K, Lüddecke J. 2016. Sensory properties of the PII signalling protein family. *FEBS J* 283:425–437. <https://doi.org/10.1111/febs.13584>.
 20. Gundlach J, Krüger L, Herzberg C, Turdiev A, Poehlein A, Tascón I, Weiss M, Hertel D, Daniel R, Hänelt I, Lee VT, Stülke J. 2019. Sustained sensing in potassium homeostasis: cyclic di-AMP controls potassium uptake by KimA at the levels of expression and activity. *J Biol Chem* 294:9605–9614. <https://doi.org/10.1074/jbc.RA119.008774>.
 21. Baykov AA, Tuominen HK, Lahti R. 2011. The CBS domain: a protein module with an emerging prominent role in regulation. *ACS Chem Biol* 6:1156–1163. <https://doi.org/10.1021/cb200231c>.
 22. Yin W, Cai X, Ma H, Zhu L, Zhang Y, Chou S-H, Galperin MY, He J. 2020. A decade of research on the second messenger c-di-AMP. *FEMS Microbiol Rev* 44:701–724. <https://doi.org/10.1093/femsre/fuaa019>.
 23. Gundlach J, Herzberg C, Kaever V, Gunka K, Hoffmann T, Weiß M, Gibhardt J, Thürmer A, Hertel D, Daniel R, Bremer E, Commichau FM, Stülke J. 2017. Control of potassium homeostasis is an essential function of the second messenger cyclic di-AMP in *Bacillus subtilis*. *Sci Signal* 10:eal3011. <https://doi.org/10.1126/scisignal.aal3011>.
 24. Krüger L, Herzberg C, Rath H, Pedreira P, Ischebeck T, Poehlein A, Gundlach J, Daniel R, Völker U, Mäder U, Stülke J. 2021. Essentiality of c-di-AMP in *Bacillus subtilis*: bypassing mutations converge in potassium and glutamate homeostasis. *PLoS Genet* 17:e1009092. <https://doi.org/10.1371/journal.pgen.1009092>.
 25. Peterson BN, Young MKM, Luo S, Wang J, Whiteley AT, Woodward JJ, Tong L, Wang JD, Portnoy DA. 2020. (p)ppGpp and c-di-AMP homeostasis is controlled by CbpB in *Listeria monocytogenes*. *mBio* 11:e01625-20. <https://doi.org/10.1128/mBio.01625-20>.
 26. Gundlach J, Mehne FM, Herzberg C, Kampf J, Valerius O, Kaever V, Stülke J. 2015. An essential poison: synthesis and degradation of cyclic di-AMP in *Bacillus subtilis*. *J Bacteriol* 197:3265–3274. <https://doi.org/10.1128/JB.00564-15>.
 27. Krüger L, Herzberg C, Warneke R, Poehlein A, Stautz J, Weiß M, Daniel R, Hänelt I, Stülke J. 2020. Two ways to convert a low affinity potassium channel to high affinity: control of *Bacillus subtilis* KtrDC by glutamate. *J Bacteriol* 202:e00138-20. <https://doi.org/10.1128/JB.00138-20>.
 28. Choi PH, Vu TMN, Pham HT, Woodward JJ, Turner MS, Tong L. 2017. Structural and functional studies of pyruvate carboxylase regulation by cyclic di-AMP in lactic acid bacteria. *Proc Natl Acad Sci U S A* 114:E7226–E7235. <https://doi.org/10.1073/pnas.1704756114>.
 29. Whiteley AT, Garelis NE, Peterson BN, Choi PH, Tong L, Woodward JJ, Portnoy DA. 2017. c-di-AMP modulates *Listeria monocytogenes* central metabolism to regulate growth, antibiotic resistance and osmoregulation. *Mol Microbiol* 104:212–233. <https://doi.org/10.1111/mmi.13622>.
 30. Gibhardt J, Hoffmann G, Turdiev A, Wang M, Lee VT, Commichau FM. 2019. c-di-AMP assists osmoadaptation by regulating the *Listeria monocytogenes* potassium transporters KimA and KtrCD. *J Biol Chem* 294:16020–16033. <https://doi.org/10.1074/jbc.RA119.010046>.
 31. Buffing MF, Link H, Christodoulou D, Sauer U. 2018. Capacity for instantaneous catabolism of preferred and non-preferred carbon sources in *Escherichia coli* and *Bacillus subtilis*. *Sci Rep* 8:11760. <https://doi.org/10.1038/s41598-018-30266-3>.
 32. Adina-Zada A, Zeczycki TN, Attwood PV. 2012. Regulation of the structure and activity of pyruvate carboxylase by acetyl-CoA. *Arch Biochem Biophys* 519:118–130. <https://doi.org/10.1016/j.abb.2011.11.015>.
 33. Adina-Zada A, Zeczycki TN, St Maurice M, Jitrapakdee S, Cleland WW, Attwood PV. 2012. Allosteric regulation of the biotin-dependent enzyme pyruvate carboxylase by acetyl-CoA. *Biochem Soc Trans* 40:567–572. <https://doi.org/10.1042/BST20120041>.
 34. Diesterhaft MD, Freese E. 1973. Role of pyruvate carboxylase, phosphoenolpyruvate carboxykinase, and malic enzyme during growth and sporulation of *Bacillus subtilis*. *J Biol Chem* 248:6062–6070. [https://doi.org/10.1016/S0021-9258\(19\)43509-6](https://doi.org/10.1016/S0021-9258(19)43509-6).
 35. Modak HV, Kelly DJ. 1995. Acetyl-CoA-dependent pyruvate carboxylase from the photosynthetic bacterium *Rhodobacter capsulatus*: rapid and efficient purification using dye-ligand affinity chromatography. *Microbiology* 141:2619–2628. <https://doi.org/10.1099/13500872-141-10-2619>.
 36. Sirithanakorn C, Adina-Zada A, Wallace JC, Jitrapakdee S, Cleland WW, Attwood PV. 2014. Mechanisms of inhibition of *Rhizobium etli* pyruvate carboxylase by L-aspartate. *Biochemistry* 53:7100–7106. <https://doi.org/10.1021/bi501113u>.
 37. Orr MW, Galperin MY, Lee VT. 2016. Sustained sensing as an emerging principle in second messenger signaling systems. *Curr Opin Microbiol* 34:119–126. <https://doi.org/10.1016/j.mib.2016.08.010>.
 38. Huynh TN, Choi PH, Sureka K, Ledvina HE, Campillo J, Tong L, Woodward JJ. 2016. Cyclic di-AMP targets the cystathionine beta-synthase domain of the osmolyte transporter OpuC. *Mol Microbiol* 102:233–243. <https://doi.org/10.1111/mmi.13456>.
 39. Schuster CF, Bellows LE, Tosi T, Campeotto I, Corrigan RM, Freemont P, Gründling A. 2016. The second messenger c-di-AMP inhibits the osmolyte uptake system OpuC in *Staphylococcus aureus*. *Sci Signal* 9:ra81. <https://doi.org/10.1126/scisignal.aaf7279>.
 40. Whiteley AT, Pollock AJ, Portnoy DA. 2015. The PAMP c-di-AMP is essential for *Listeria monocytogenes* growth in rich but not minimal media due to a toxic increase in (p)ppGpp. *Cell Host Microbe* 17:788–798. <https://doi.org/10.1016/j.chom.2015.05.006>.
 41. Selim KA, Haffner M, Burkhardt M, Mantovani O, Neumann N, Albrecht R, Seifer R, Krüger L, Stülke J, Hartmann MD, Hagemann M, Forchhammer K. 2021. Diurnal metabolic control in cyanobacteria requires perception of second messenger signaling molecule c-di-AMP by the carbon control protein SbtB. *Sci Adv* 7:eabk0568. <https://doi.org/10.1126/sciadv.abk0568>.
 42. Sambrook J, Fritsch EF, Maniatis T. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
 43. Kunst F, Rapoport G. 1995. Salt stress is an environmental signal affecting degradative enzyme synthesis in *Bacillus subtilis*. *J Bacteriol* 177:2403–2407. <https://doi.org/10.1128/jb.177.9.2403-2407.1995>.
 44. Bi W, Stambrook PJ. 1998. Site-directed mutation by combined chain reaction. *Anal Biochem* 256:137–140. <https://doi.org/10.1006/abio.1997.2516>.
 45. Diethmaier C, Pietack N, Gunka K, Wrede C, Lehnik-Habrink M, Herzberg C, Hübner S, Stülke J. 2011. A novel factor controlling bistability in *Bacillus subtilis*: the YmdB protein affects flagellin expression and biofilm formation. *J Bacteriol* 193:5997–6007. <https://doi.org/10.1128/JB.05360-11>.
 46. Herzberg C, Weidinger LA, Dörrbecker B, Hübner S, Stülke J, Commichau FM. 2007. SPINE: a method for the rapid detection and analysis of protein-protein interactions *in vivo*. *Proteomics* 7:4032–4035. <https://doi.org/10.1002/pmic.200700491>.
 47. Schirmer F, Ehrst S, Hillen W. 1997. Expression, inducer spectrum, domain structure, and function of MopR, the regulator of phenol degradation in *Acinetobacter calcoaceticus* NCIB8250. *J Bacteriol* 179:1329–1336. <https://doi.org/10.1128/jb.179.4.1329-1336.1997>.
 48. Wyatt BN, Arnold LA, St Maurice M. 2018. A high-throughput screening assay for pyruvate carboxylase. *Anal Biochem* 550:90–98. <https://doi.org/10.1016/j.ab.2018.04.012>.
 49. Bradford MM. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72:248–254. [https://doi.org/10.1016/0003-2697\(76\)90527-3](https://doi.org/10.1016/0003-2697(76)90527-3).
 50. Schmalisch M, Langbein I, Stülke J. 2002. The general stress protein Ctc of *Bacillus subtilis* is a ribosomal protein. *J Mol Microbiol Biotechnol* 4:495–501.
 51. Shevchenko A, Wilm M, Vorm O, Mann M. 1996. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. *Anal Chem* 68:850–858. <https://doi.org/10.1021/ac950914h>.
 52. Rappsilber J, Ishihama Y, Mann M. 2003. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. *Anal Chem* 75:663–670. <https://doi.org/10.1021/ac026117i>.

53. Rappsilber J, Mann M, Ishihama Y. 2007. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using Stage-Tips. *Nat Protoc* 2:1896–1906. <https://doi.org/10.1038/nprot.2007.261>.
54. Kohlstedt M, Sappa PK, Meyer H, Maaß S, Zapras A, Hoffmann T, Becker J, Steil L, Hecker M, van Dijk JM, Lalk M, Mäder U, Stülke J, Bremer E, Völker U, Wittmann C. 2014. Adaptation of *Bacillus subtilis* carbon core metabolism to simultaneous nutrient limitation and osmotic challenge: a multi-omics perspective. *Environ Microbiol* 16:1898–1917. <https://doi.org/10.1111/1462-2920.12438>.
55. Reuß DR, Altenbuchner J, Mäder U, Rath H, Ischebeck T, Sappa PK, Thürmer A, Guérin C, Nicolas P, Steil L, Zhu B, Feussner I, Klumpp S, Daniel R, Commichau FM, Völker U, Stülke J. 2017. Large-scale reduction of the *Bacillus subtilis* genome: consequences for the transcriptional network, resource allocation, and metabolism. *Genome Res* 27:289–299. <https://doi.org/10.1101/gr.215293.116>.
56. Bellaire A, Ischebeck T, Staedler Y, Weinhaeuser I, Mair A, Parameswaran S, Ito T, Schönenberger J, Weckwerth W. 2014. Metabolism and development – integration of micro computed tomography data and metabolite profiling reveals metabolic reprogramming from floral initiation to silique development. *New Phytol* 202:322–335. <https://doi.org/10.1111/nph.12631>.
57. Touraine B, Vignols F, Przybyla-Toscano J, Ischebeck T, Dhalleine T, Wu HC, Magno C, Berger N, Couturier J, Dubos C, Feussner I, Caffarri S, Havaux M, Rouhier N, Gaymard F. 2019. Iron-sulfur protein NFU2 is required for branched-chain amino acid synthesis in *Arabidopsis* roots. *J Exp Bot* 70:1875–1889. <https://doi.org/10.1093/jxb/erz050>.
58. Kopka J, Schauer N, Krueger S, Birkemeyer C, Usadel B, Bergmüller E, Dörmann P, Weckwerth W, Gibon Y, Stitt M, Willmitzer L, Fernie AR, Steinhauser D. 2005. GMD@CSB.DB: the Golm metabolome database. *Bioinformatics* 21:1635–1638. <https://doi.org/10.1093/bioinformatics/bti236>.
59. Roelofs KG, Wang J, Sintim HO, Lee VT. 2011. Differential radial capillary action of ligand assay for high-throughput detection of protein-metabolite interactions. *Proc Natl Acad Sci U S A* 108:15528–15533. <https://doi.org/10.1073/pnas.1018949108>.
60. Orr MW, Lee VT. 2017. Differential radial capillary action of ligand assay (DRaCALA) for high-throughput detection of protein-metabolite interactions in bacteria. *Methods Mol Biol* 1535:25–41. https://doi.org/10.1007/978-1-4939-6673-8_3.